Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report

BACKGROUND: Growth hormone deficiency (GHD) is associated with non-alcoholic fatty liver disease (NAFLD). A recent animal study showed that hepatocyte-specific receptor activator of nuclear factor-kappa B (RANK) knockout mice had significantly lower liver fat content compared with control mice conco...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeno, Ayumu, Yamamoto, Masahiro, Notsu, Masakazu, Sugimoto, Toshitsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122017/
https://www.ncbi.nlm.nih.gov/pubmed/27881164
http://dx.doi.org/10.1186/s12902-016-0148-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122017/
https://www.ncbi.nlm.nih.gov/pubmed/27881164
http://dx.doi.org/10.1186/s12902-016-0148-0

Ejemplares similares